Recommandations pour le traitement médicamenteux de l'incontinence urinaire non neurologique féminine

25 février 2010

Auteurs : S. Conquy
Référence : Prog Urol, 2010, 20, S100, suppl. S2


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser


Steinauer J.E., Waetjen L.E., Vittinghoff E., Subak L.L., Hulley S.B., Grady D., et al. Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol 2005 ;  106 : 940-945 [cross-ref]
Hendrix S.L., Cochrane B.B., Nygaard I.E., Handa V.L., Barnabei V.M., Iglesia C., et al. Effects of estrogen with and without progestin on urinary incontinence JAMA 2005 ;  293 : 935-948 [cross-ref]
Goldstein S.R., Johnson S., Watts N.B., Ciaccia A.V., Elmerick D., Muram D. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen Menopause 2005 ;  12 : 160-164 [cross-ref]
Moehrer B., Hextall A., Jackson S. Oestrogens for urinary incontinence in women Cochrane Database Syst Rev 2003 ; CD001405.
Holtedahl K., Verelst M., Schiefloe A. A population based, randomized, controlled trial of conservative treatment for urinary incontinence in women Acta Obstet Gynecol Scand 1998 ;  77 : 671-677 [cross-ref]
Akhila V., Pratakumar A comparison of transdermal and oral HRT for menopausal symptom control Int J Fertil Womens Med 2006 ;  51 : 64-69
Ballagh S.A. Vaginal hormone therapy for urogenital and menopausal symptoms Semin Reprod Med 2005 ;  23 : 126-140 [cross-ref]
Stevenson J.C. HRT and cardiovascular disease Best Pract Res Clin Obstet Gynaecol 2009 ;  23 : 109-120 [cross-ref]
Tseng L.H., Wang A.C., Chang Y.L., Soong Y.K., Lloyd L.K., Ko Y.J. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome Neurourol Urodyn 2009 ;  28 : 47-51 [cross-ref]
Alhasson A., Glazener C.M., Pickard R., N’Dow J. Adrenergic drugs for urinary incontinence in adults Cochrane Database Syst Rev 2005 ; CD001842.
Dubeau C.E., Khullar V., Versi E. «Unblinding» in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident Neurourol Urodyn 2005 ;  24 : 13-20 [cross-ref]
Ishiko O., Ushiroyama T., Saji F., Mitsuhashi Y., Tamura T., Yamamoto K., Kawamura Y., Ogita S. beta(2)-adrenergic agonists and pelvic floor exercises for female stress incontinence Int J Gynaecol Obstet 2000 ;  71 : 39-44 [cross-ref]
Mariappan P., Alhasso A., Ballantyne Z., Grant A., N’Dow J. Duloxetine a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review Eur Urol 2007 ;  51 : 67-74 [cross-ref]
Athanasopoulos A., Perimenis P. Pharmacotherapy of urinary incontinence Int Urogynecol J Pelvic Floor Dysfunct 2009 ;  20 : 475-482 [cross-ref]
Drutz H. Duloxetine in women awaiting surgery Bjog 2006 ;  113 (Suppl 1) : 17-21 [cross-ref]
Ghoniem G.M., Van Leeuwen J.S., Elser D.M., Freeman R.M., Zhao Y.D., Yalcin I., et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence J Urol 2005 ;  173 : 1647-1653 [cross-ref]
Mariappan P., Ballantyne Z., N’Dow J.M., Alhasso A.A. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults Cochrane Database Syst Rev 2005 ; CD004742.
Millard R.J., Moore K., Rencken R., Yalcin I., Bump R.C. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial BJU Int 2004 ;  93 : 311-318 [cross-ref]
Steers W.D., Herschorn S., Kreder K.J., Moore K., Strohbehn K., Yalcin I., et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder BJU Int 2007 ;  100 : 337-345 [cross-ref]
Muhlstein J., Deval B. Anticholinergic drugs in overactive bladder Gynecol Obstet Fertil 2008 ;  36 : 90-96 [cross-ref]
Nabi G., Cody J.D., Ellis G., Herbison P., Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults Cochrane Database Syst Rev 2006 ; CD003781.
Cardozo L., Hessdorfer E., Milani R., Arano P., Dewilde L., Slack M., et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial BJU Int 2008 ;
Burgio K.L., Locher J.L., Goode P.S., Hardin J.M., McDowell B.J., Dombrowski M., et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial JAMA 1998 ;  280 : 1995-2000 [cross-ref]
Anderson R.U., Mobley D., Blank B., Saltzstein D., Susset J., Brown J.S. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group J Urol 1999 ;  161 : 1809-1812 [cross-ref]
Khullar V., Hill S., Laval K.U., Schiotz H.A., Jonas U., Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebocontrolled trial Urology 2004 ;  64 : 269-274discussion 74-5.
Novara G., Galfano A., Secco S., D’Elia C., Cavalleri S., Ficarra V., et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder Eur Urol 2008 ;  54 : 740-763 [cross-ref]
Chapple C.R., Khullar V., Gabriel Z., Muston D., Bitoun C.E., Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 2008 ;  54 : 543-562 [cross-ref]
Roxburgh C., Cook J., Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults Cochrane Database Syst Rev 2007 ; CD003190.

© 2010 
Elsevier Masson SAS. Tous droits réservés.